Literature DB >> 3489749

Nursing home-acquired pneumonia. A case-control study.

T J Marrie, H Durant, C Kwan.   

Abstract

To determine if there are any unique features of nursing home-acquired pneumonia we carried out a case-control study wherein each patient admitted with nursing home-acquired pneumonia was age- and sex-matched with a patient with community-acquired pneumonia. There were 36 men and 38 women in the nursing home group. The mean age of both groups was 74 years. The mortality rate for nursing home-acquired pneumonia it was 40.5%, whereas for community-acquired pneumonia it was 28% (P = NS). Patients with nursing home-acquired pneumonia had a significantly higher incidence of dementia and cerebrovascular accidents, and patients with community-acquired pneumonia were more likely to be smokers and to have chronic obstructive pulmonary disease. Aspiration pneumonia was more common among patients with nursing home-acquired pneumonia (P less than .001), and Hemophilus influenza pneumonia more common among the patients with community-acquired infection (P less than .01). Sputum for culture could be obtained in only 31 and 39% of the patients--contributory to the high rates of pneumonia of unknown etiology 63.5 and 56.1% for the nursing home group and the control subjects, respectively. Patients with nursing home-acquired pneumonia received cloxacillin and aminoglycosides more frequently than patients with community-acquired pneumonia (P less than .05), and patients with community-acquired pneumonia received erythromycin more frequently than patients with nursing home-acquired pneumonia (P less than .05). Complications were common during the hospital stay of these patients--the most frequent being congestive heart failure, urinary tract infection, renal failure, and respiratory failure.

Entities:  

Mesh:

Year:  1986        PMID: 3489749     DOI: 10.1111/j.1532-5415.1986.tb04300.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  26 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Response to Kasprisin et al.: the efficacy of rehabilitative management of dysphagia.

Authors:  K Silver; A S DuChane; K Kuhlemeier
Journal:  Dysphagia       Date:  1990       Impact factor: 3.438

Review 3.  Nursing home-acquired pneumonia. Treatment options.

Authors:  T J Marrie; K L Slayter
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 4.  Nursing home-acquired pneumonia: update on treatment options.

Authors:  Joseph M Mylotte
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

5.  A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.

Authors:  J D McCue; P Gaziano; D Orders
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  Problems in diagnosing infections in the elderly.

Authors:  D J Flournoy; M A Bernard
Journal:  J Natl Med Assoc       Date:  1993-11       Impact factor: 1.798

7.  Quality of published reports of the prognosis of community-acquired pneumonia.

Authors:  C A Carson; M J Fine; M A Smith; L A Weissfeld; J T Huber; W N Kapoor
Journal:  J Gen Intern Med       Date:  1994-01       Impact factor: 5.128

8.  Use of videofluoroscopic swallowing study in patients with aspiration pneumonia.

Authors:  Seunglee Park; Jin-Youn Lee; Heeyoune Jung; Seong-Eun Koh; In-Sik Lee; Kwang Ha Yoo; Seung Ah Lee; Jongmin Lee
Journal:  Ann Rehabil Med       Date:  2012-12-28

9.  Infectious diseases and mortality among US nursing home residents.

Authors:  C Beck-Sague; S Banerjee; W R Jarvis
Journal:  Am J Public Health       Date:  1993-12       Impact factor: 9.308

Review 10.  Low zinc status: a new risk factor for pneumonia in the elderly?

Authors:  Junaidah B Barnett; Davidson H Hamer; Simin N Meydani
Journal:  Nutr Rev       Date:  2010-01       Impact factor: 7.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.